Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Status:
Active, not recruiting
Trial end date:
2023-08-21
Target enrollment:
Participant gender:
Summary
Axitinib is a drug which is approved by the FDA for patients with advanced kidney cancer who
have already received some treatment. It works by reducing blood flow to a tumor. Axitinib is
normally give at 5mg twice per day and sometimes this dose is increased if patients tolerate
it. The purpose of this study is to figure out a different way to decide which dose of
axitinib each patient should receive based on the side effects they experience.